Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Healthcare Biotechnology Medical Instruments & Supplies
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Spectral Medical Inc > Glaring Mismatch…
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(137)
•••
Comment by Domino55on Mar 24, 2022 2:20pm
181 Views
Post# 34542424

RE:RE:RE:RE:RE:RE:RE:Glaring Mismatch…

RE:RE:RE:RE:RE:RE:RE:Glaring Mismatch…Hmmmmm... 

Back out of the fog of frustration for a second and look down from above-

Tigris- although recruitment is slow it's Going great, much better than anticipated from a results perspective with a satisfied partner in Baxter

Dimi Trial - Partner to come, DSMB in place and only a 12 week trial. A "WHEN NOT IF" proposition 

so now you have fully loaded management who just repeated that both of the above are multi billion dollar opportunities. Both. 

I re read the release and I think AP is on to something. I have always thought Spectral would be bought out before these trial's are completed and more so now. Much more so.

I think Kellum is back at Pitt March of 2023.

I think it might just be a 30 bagger - or more.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities